![]() Fmoc-Leu-OH structure
|
Common Name | Fmoc-Leu-OH | ||
---|---|---|---|---|
CAS Number | 35661-60-0 | Molecular Weight | 353.412 | |
Density | 1.2±0.1 g/cm3 | Boiling Point | 559.8±33.0 °C at 760 mmHg | |
Molecular Formula | C21H23NO4 | Melting Point | 152-156 °C(lit.) | |
MSDS | Chinese USA | Flash Point | 292.4±25.4 °C |
Use of Fmoc-Leu-OHFmoc-leucine is a selective PPARγ modulator. Fmoc-leucine activates PPARγ with a lower potency but a similar maximal efficacy than rosiglitazone. Fmoc-leucine improves insulin sensitivity in normal, diet-induced glucose-intolerant, and in diabetic db/db mice. Fmoc-leucine has a lower adipogenic activity[1]. |
Name | (2S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-4-methylpentanoic acid |
---|---|
Synonym | More Synonyms |
Description | Fmoc-leucine is a selective PPARγ modulator. Fmoc-leucine activates PPARγ with a lower potency but a similar maximal efficacy than rosiglitazone. Fmoc-leucine improves insulin sensitivity in normal, diet-induced glucose-intolerant, and in diabetic db/db mice. Fmoc-leucine has a lower adipogenic activity[1]. |
---|---|
Related Catalog | |
Target |
PPARγ |
References |
Density | 1.2±0.1 g/cm3 |
---|---|
Boiling Point | 559.8±33.0 °C at 760 mmHg |
Melting Point | 152-156 °C(lit.) |
Molecular Formula | C21H23NO4 |
Molecular Weight | 353.412 |
Flash Point | 292.4±25.4 °C |
Exact Mass | 353.162720 |
PSA | 75.63000 |
LogP | 4.95 |
Vapour Pressure | 0.0±1.6 mmHg at 25°C |
Index of Refraction | 1.583 |
Storage condition | 2~8°C |
Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
---|---|
Hazard Codes | Xi |
Risk Phrases | R36/37/38 |
Safety Phrases | S22-S24/25 |
RIDADR | NONH for all modes of transport |
WGK Germany | 3 |
HS Code | 2924299090 |
Precursor 7 | |
---|---|
DownStream 10 | |
HS Code | 2924299090 |
---|---|
Summary | 2924299090. other cyclic amides (including cyclic carbamates) and their derivatives; salts thereof. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:30.0% |
Aspartate-modified doxorubicin on its N-terminal increases drug accumulation in LAT1-overexpressing tumors.
Cancer Sci. 106 , 747-56, (2015) L-type amino acid transporter 1 (LAT1), overexpressed on the membrane of various tumor cells, is a potential target for tumor-targeting therapy. This study aimed to develop a LAT1-mediated chemotherap... |
|
Ceramide as a mediator of non-alcoholic Fatty liver disease and associated atherosclerosis.
PLoS ONE 10 , e0126910, (2015) Cardiovascular disease (CVD) is a serious comorbidity in nonalcoholic fatty liver disease (NAFLD). Since plasma ceramides are increased in NAFLD and sphingomyelin, a ceramide metabolite, is an indepen... |
|
Correlations of amyloid-β concentrations between CSF and plasma in acute Alzheimer mouse model.
Sci. Rep. 4 , 6777, (2014) Amyloid-β (Aβ) is one of the few neuropathological biomarkers associated with transporters of the blood-brain barrier (BBB). Despite the well-characterized clinical indication of decreasing Aβ levels ... |
D-LeuFmoc-OH |
Fmoc-Leu-OH |
N-((9H-Fluoren-9-ylmethoxy)carbonyl)-L-leucine |
EINECS 252-662-7 |
(S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-4-methylpentanoic acid |
MFCD00037133 |
Tocris-0675 |
FMOC-D-LEU |
Fmoc-D-Leu-OH |
Fmoc-L-leucine |
Fmoc-L-Leu-OH |
L-Leucine, N-[(9H-fluoren-9-ylmethoxy)carbonyl]- |
N-[(9H-Fluoren-9-ylmethoxy)carbonyl]-D-leucine |
Fmoc-D-leucine-OH |
N-Fmoc-D-leucine |
D-Fmoc-Leu-OH |
N-Fmoc-L-leucine |
D-Leucine, N-[(9H-fluoren-9-ylmethoxy)carbonyl]- |
Fmoc-D-Leucine |
N-[(9H-Fluoren-9-ylmethoxy)carbonyl]-L-leucine |